145 related articles for article (PubMed ID: 9241361)
1. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Rucińska M; Furman M; Skrzydlewski Z; Zaremba E
Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361
[TBL] [Abstract][Full Text] [Related]
2. [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer].
Kozuszko B; Skrzydlewski Z; Sulkowska M; Snarska J; Kozłowski M; Skrzydlewska E; Zalewski B
Pol Merkur Lekarski; 2001 Sep; 11(63):218-20. PubMed ID: 11761814
[TBL] [Abstract][Full Text] [Related]
3. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker.
Gordon SG; Cross BA
Cancer Res; 1990 Oct; 50(19):6229-34. PubMed ID: 2169340
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic significance of cancer procoagulant activity in colorectal cancer].
Kozuszko B; Skrzydlewski Z; Famulski W
Pol Merkur Lekarski; 2000 Mar; 8(45):127-8. PubMed ID: 10870414
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system].
Szajda SD; Darewicz B; Kudelski J; Werel T; Zwierz K; Skrzydlewski Z; Gabrylewski W
Pol Merkur Lekarski; 2005 Oct; 19(112):596-9. PubMed ID: 16379335
[TBL] [Abstract][Full Text] [Related]
6. [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer].
Szajda SD; Darewicz B; Kudelski J; Chlabicz M; Domel T; Chabielska E; Skrzydlewski Z
Pol Merkur Lekarski; 2005 Jun; 18(108):651-3. PubMed ID: 16124376
[TBL] [Abstract][Full Text] [Related]
7. Cancer procoagulant (CP) in lung cancer.
Rucińska M; Skrzydlewski Z; Zaremba E; Furman M; Kasacka I
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():251-3. PubMed ID: 9337542
[TBL] [Abstract][Full Text] [Related]
8. [Hepatocyte growth factor in the sera of patients with gastrointestinal and breast cancer].
Narita T; Toi M; Sekiguchi K; Iwanari H; Matsuura N; Kimura N; Mitsuoka C; Kannagi R
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2159-62. PubMed ID: 9388530
[No Abstract] [Full Text] [Related]
9. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.
Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN
Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088
[TBL] [Abstract][Full Text] [Related]
10. [Usefulness of detecting cancer procoagulant activity and thyrotropic hormone concentration in the differentiation of tumor-like changes in the thyroid].
Snarska J; Szajda SD; Knaś M; Mroczko B; Borzym-Kluczyk M; Kamiński F; Zwierz P; Zwierz K
Wiad Lek; 2006; 59(5-6):332-5. PubMed ID: 17017477
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of examination of some tumor markers in diagnostics of liver cancer.
Snarska J; Szajda SD; Puchalski Z; Szmitkowski M; Chabielska E; Kaminski F; Zwierz P; Zwierz K
Hepatogastroenterology; 2006; 53(68):271-4. PubMed ID: 16608038
[TBL] [Abstract][Full Text] [Related]
12. Procoagulant activity in whole blood from patients with breast and colorectal cancer.
Parmar J; Taylor I; Roath S; Francis J
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):127-32. PubMed ID: 2130924
[TBL] [Abstract][Full Text] [Related]
13. Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer.
Kozuszko B; Skrzydlewska E; Snarska J; Kozłowski M; Zalewski B; Skrzydlewski Z
Folia Histochem Cytobiol; 2001; 39 Suppl 2():104-5. PubMed ID: 11820560
[TBL] [Abstract][Full Text] [Related]
14. [Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)].
Gołab K; Passowicz-Muszyńska E; Jankowska R; Warwas M
Pol Merkur Lekarski; 2009 Mar; 26(153):194-7. PubMed ID: 19388531
[TBL] [Abstract][Full Text] [Related]
15. [Cancer procoagulant (CP)].
Szajda SD; Darewicz B; Gorzel M; Zalewska B; Skrzydlewski Z; Kudelski J; Domel T
Przegl Lek; 2005; 62(3):169-72. PubMed ID: 16171148
[TBL] [Abstract][Full Text] [Related]
16. Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes.
Chojnowski K; Treliński J; Wawrzyniak E; Sobolewska M; Mielicki W
Neoplasma; 2002; 49(3):155-8. PubMed ID: 12098000
[TBL] [Abstract][Full Text] [Related]
17. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study.
Pazdiora P; Svobodova S; Fuchsova R; Kucera R; Prazakova M; Vrzalova J; Narsanska A; Strakova M; Treskova I; Pecen L; Treska V; Holubec L; Pesek M; Finek J; Topolcan O
Anticancer Res; 2011 Oct; 31(10):3619-21. PubMed ID: 21965787
[TBL] [Abstract][Full Text] [Related]
19. New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors.
Mielicki WP; Tagawa M; Gordon SG
Thromb Haemost; 1994 Apr; 71(4):456-60. PubMed ID: 8052963
[TBL] [Abstract][Full Text] [Related]
20. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients.
Rohayem J; Diestelkoetter P; Weigle B; Oehmichen A; Schmitz M; Mehlhorn J; Conrad K; Rieber EP
Cancer Res; 2000 Apr; 60(7):1815-7. PubMed ID: 10766164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
